Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Patent
1993-04-01
1995-10-03
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
4241331, 4241341, 4241811, 4241831, 435 696, 435 7021, 4351723, 43524027, 5303873, 5303917, A61K 39395, C07K 1600, C07K 1646
Patent
active
054550300
ABSTRACT:
The invention pertains to a single polypeptide chain binding molecule which has binding specificity and affinity substantially similar to the binding specificity and affinity of the light and heavy chain aggregate variable region of an antibody, to genetic sequences coding therefor, and to recombinant DNA methods of producing such molecule and uses for such molecule.
REFERENCES:
patent: 4085443 (1978-04-01), Dubois et al.
patent: 4266253 (1981-05-01), Matherat
patent: 4355023 (1982-10-01), Ehrlich et al.
patent: 4414629 (1983-11-01), Waite
patent: 4434156 (1984-02-01), Trowbridge
patent: 4444878 (1984-04-01), Paulus
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4479895 (1984-10-01), Auditore-Hargreaves
patent: 4507234 (1985-03-01), Kato et al.
patent: 4638049 (1987-01-01), Masuho et al.
patent: 4642334 (1987-02-01), Moore et al.
patent: 4704692 (1989-01-01), Ladner et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4853871 (1989-08-01), Pantoliano et al.
patent: 4908773 (1990-03-01), Pantoliano et al.
patent: 4939666 (1990-07-01), Hardman
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5260203 (1993-11-01), Ladner et al.
Osband, et al., "Problems in the Investigational Study and Clinical Use of Cancer Immunotherapy", Immunology Today, 11(6):193-195, 1990.
Waldman, T. A., "Monoclonal Antibodies in Diagnosis and Therapy", Science, vol. 252:1657-1662, 21 Jun. 1991.
Dillman, R. D., "Monoclonal Antibodies for Treating Cancer", Annals of Internal Medicine, vol. 111:592-603, 1989.
Hind et al., "Immunotherapy with Monoclonal Antibodies", in Genes and Cancer, Carney et al., Eds., Wiley & Sons, 1990.
Physician's Desk Reference, 48th Ed., 1994.
Friedman et al., J. Immunology, 150:3054-3061, Apr. 1, 1991.
Kreitman et al., Blood, 83(2):426-443, 1994.
Wels et al., Cancer Research, 52:6310-6317, Nov. 15, 1992.
Batra et al., Proc. Nat'l. Acad. Sci., USA, 89:5867-5871, Jul. 1992.
Holvoet et al., Blood, 81(3):696-703, Feb. 1, 1993.
Munro, A., "Uses of chimaeric antibodies", Nature, 312:597 (Dec. 1984).
Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies", Science, 229:1202-1207 (1985).
Morrison, S. L., et al., "Chimeric human antibody molecuees: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA, 81:6851-6855 (Nov. 1984).
Oi, V. T. et al., "Chimeric Antibodies", Biotechniques, 4(3):214-221 (1986).
Wood, C. R. et al., "The synthesis and in vivo assembly of functional antibodies in yeast", Nature, 314:446-449 (1985).
Huber, R., "Structural Basis for Antigen-Antibody Recognition", Science, 223:702-703 (1986).
Van Brunt, J., "Protein Architecture: Designing From The Ground Up", Bio/Technol., 4(4):227-283 (Apr. 1986).
Boulianne, G. L., "Production of functional chimaeric mouse/human antibody", Nature, 312:643-646 (Dec. 1984).
Boss, M. A., et al., "Assembly of functional antibodies from immunoglobulin heavy and light chains synthesised in E. coli", Nucl. Acids Res., 12:3791-3805 (1984).
Neuberger, M. S. et al., "Recombinant antibodies possessing novel effector functions", Nature, 312:604-608 (Dec. 1984).
Creative BioMolecules, Inc. Phase I SBIR Grant Title Page/Abstract (1985).
Creative BioMolecules, Inc. Phase II SBIR Grant Title Page/Abstract (1986).
Bird, R. E. et al., "Single-Chain Antigen-Binding Proteins", Science, 242:423-426 (1988).
"Nothing to lose but their chains", The Economist, Feb. 27, 1988.
Bishop, J., The Wall Street Journal, "Proteins made by Genex could compete with far larger monoclonal antibodies", Oct. 21, 1988.
Huston, J. S. et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA, 85:5879-5883 (1988).
Aldred, A. R. et al., "Adenovirus-2 E1A products repress enhancer-induced stimulation of transcription", Chem. Abstracts 101:185187m (Dec. 1984).
Kuhn, L. C. et al., "Gene Transfer, Expression, and Molecular Cloning of the Human Transferrin Receptor Gene", Cell 37:95-103 (1984).
Field, H. et al., "Miniantibodies produced in Escherichia coli--fusion protein expression using dual origin vector", Biotechnology Abstracts #89-05519 (1987).
Huston, J. S., "Biosynthetic antibody sites: studies of an anti-digoxin Fv region--recombinant monoclonal antibody preparation", Biotechnology Abstracts #87-11664 (1987).
Field, H. et al., "Miniantibodies produced in Escherichia coli--hen egg lysozyme variable region monoclonal antibody gene cloning in Escherichia coli, application for characterization", Biotechnology Abstracts #87-12016 (1987).
Kausner, A., "Single-Chain Antibodies Become a Reality", Bio/Technol. 4:1041-1043 (Dec. 1986).
Sukhatme, U. P. et al., "The T Cell Differentiation Antigen Leu-2/T8 Is Homologous to Immunoglobulin and T Cell Receptor Variable Regions", Cell 40:591-597 (Mar. 1985).
Maddon, P. J. et al., "The Isolation and Nucleotide Sequence of a cDNA Encoding the T Cell Surface Protein T4: A New Member of the Immunoglobulin Gene Family", Cell, 42:93-104 (Aug. 1985).
Davies et al., Ann. Rev. Immunol. 1:87 (1983).
Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer:259-280 (1987).
Vitetta et al., "Immunotoxins, a new approach to cancer therapy", Science, 219:644 (1983).
Pastan et al., "Immunotoxins", Cell, 47:641 (1986).
Bird Robert E.
Hardman Karl
Ladner Robert C.
Budens Robert D.
Enzon Labs Inc.
LandOfFree
Immunotheraphy using single chain polypeptide binding molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunotheraphy using single chain polypeptide binding molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotheraphy using single chain polypeptide binding molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1076049